It's not just AI — China's quickly gaining an edge over the U.S. in biotech

Nice to see what can be accomplished in a country that isn't openly hostile to science.

China’s biotech industry has evolved to the point that U.S. and European pharmaceutical giants in the last several months have spent billions to acquire China-developed drugs that could treat cancer if commercialized with regulatory approval. In March, British pharmaceutical giant AstraZeneca announced it will invest $2.5 billion in a research and development center in Beijing.

In case you thought research isn't subject to outsourcing.